Tobira Therapeutics (TBRA) Reports Q2 Loss Per Share of $0.99
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Tobira Therapeutics Reports Second Quarter 2015 Financial Results
August 11, 2015 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., Aug. 11, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for nonalcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the second quarter of 2015.
"We successfully completed the transition to a public company, backed by a group of highly regarded investors, providing us with the financial resources needed to continue advancing cenicriviroc (CVC) as a platform for multiple high unmet need indications in liver, immuno-inflammatory and... More
